VAXCELL-BIO THERAPEUTICS CO., LTD. Financials Vaxcell-Bio Therapeutics Co., Ltd.
Equities
A323990
KR7323990002
Biotechnology & Medical Research
|
End-of-day quote
Other stock markets
|
5-day change | 1st Jan Change | ||
| 19,390 KRW | +1.78% |
|
+23.74% | -13.63% |
| 2023 | Vaxcell-Bio Therapeutics Co., Ltd. Reports Earnings Results for the First Quarter Ended March 31, 2023 | CI |
| 2021 | Vaxcell-Bio Therapeutics Co., Ltd.(KOSDAQ:A323990) added to S&P Global BMI Index | CI |
Valuation
| Fiscal Period: December | 2020 | 2021 | 2022 | 2023 |
|---|---|---|---|---|
| Capitalization 1 | 2,517,196 | 660,678 | 519,865 | 516,197 |
| Enterprise Value (EV) 1 | 2,498,632 | 633,590 | 499,579 | 466,512 |
| P/E ratio | -238 x | -115 x | -63.5 x | -42.9 x |
| Yield | - | - | - | - |
| Capitalization / Revenue | - | - | - | 37,614,610,750 x |
| EV / Revenue | - | - | - | 33,994,130,725 x |
| EV / EBITDA | -614 x | -112 x | -63.2 x | -42 x |
| EV / FCF | -1,090 x | -98.5 x | -107 x | -66 x |
| FCF Yield | -0.09% | -1.02% | -0.93% | -1.51% |
| Price to Book | 36.3 x | 22 x | 22.3 x | 6.17 x |
| Nbr of stocks (in thousands) | 18,055 | 18,268 | 18,268 | 22,993 |
| Reference price 2 | 139,417 | 36,167 | 28,458 | 22,450 |
| Announcement Date | 3/1/21 | 3/1/22 | 3/1/23 | 2/29/24 |
1KRW in Million2KRW
Estimates
Income Statement Evolution (Annual data)
| Fiscal Period: December | 2020 | 2021 | 2022 | 2023 |
|---|---|---|---|---|
| Net sales | - | - | - | 13.72 |
| EBITDA 1 | -4,070 | -5,647 | -7,901 | -11,107 |
| EBIT 1 | -4,255 | -5,904 | -8,213 | -11,507 |
| Operating Margin | - | - | - | -83,851.26% |
| Earnings before Tax (EBT) 1 | -3,984 | -4,763 | -6,825 | -10,274 |
| Net income 1 | -3,984 | -4,763 | -6,825 | -10,274 |
| Net margin | - | - | - | -74,865.84% |
| EPS 2 | -585.5 | -315.2 | -448.3 | -523.8 |
| Free Cash Flow 1 | -2,291 | -6,434 | -4,650 | -7,065 |
| FCF margin | - | - | - | -51,478.51% |
| FCF Conversion (EBITDA) | - | - | - | - |
| FCF Conversion (Net income) | - | - | - | - |
| Dividend per Share | - | - | - | - |
| Announcement Date | 3/1/21 | 3/1/22 | 3/1/23 | 2/29/24 |
1KRW in Million2KRW
Estimates
Balance Sheet Analysis
| Fiscal Period: December | 2020 | 2021 | 2022 | 2023 |
|---|---|---|---|---|
| Net Debt 1 | - | - | - | - |
| Net Cash position 1 | 18,563 | 27,088 | 20,287 | 49,685 |
| Leverage (Debt/EBITDA) | - | - | - | - |
| Free Cash Flow 1 | -2,291 | -6,434 | -4,650 | -7,065 |
| ROE (net income / shareholders' equity) | -18.2% | -14.7% | -25.6% | -19.2% |
| ROA (Net income/ Total Assets) | -11.7% | -11.1% | -18.5% | -13.2% |
| Assets 1 | 34,108 | 43,093 | 36,858 | 77,959 |
| Book Value Per Share 2 | 3,840 | 1,647 | 1,277 | 3,636 |
| Cash Flow per Share 2 | 1,097 | 126.0 | 21.30 | 394.0 |
| Capex 1 | 26.9 | 2,124 | 167 | 166 |
| Capex / Sales | - | - | - | 1,208.17% |
| Announcement Date | 3/1/21 | 3/1/22 | 3/1/23 | 2/29/24 |
1KRW in Million2KRW
Estimates
EPS & Dividend
Year-on-year evolution of the PER
Change in Enterprise Value/EBITDA
| 1st Jan change | Capi. | |
|---|---|---|
| -13.63% | 327M | |
| +9.41% | 114B | |
| +13.38% | 107B | |
| -8.99% | 22.22B | |
| -1.54% | 21.28B | |
| -4.50% | 18.8B | |
| -5.68% | 17.51B | |
| -39.93% | 17.17B | |
| +7.01% | 14.14B | |
| +34.50% | 12.2B |
- Stock Market
- Equities
- A323990 Stock
- Financials Vaxcell-Bio Therapeutics Co., Ltd.
